Profile of TENAX THERAPEUTICS INC(NASDAQ:TENX) stock

TENAX THERAPEUTICS INC1.75

NASDAQ:TENX (2/3/2023, 7:10:48 PM)-0.46 (-20.81%)

After market: 1.8 +0.05 (+2.86%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS Sector	Health Care
GICS Industry	Biotechnology

Chartmill FA Rating

Valuation		Growth
Profitability		Health
Dividend

Overview

Earnings (Last)	11-10 2022-11-10/amc	Earnings (Next)	03-27 2023-03-27/amc
Ins Owners	203.87%	Inst Owners	151.22%
Market Cap	4.01M	Shares	2.29M
PE	N/A	Fwd PE	N/A
Dividend Yield	N/A	Analysts	82.86
IPO	10-28 1993-10-28

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Tenax Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Chapel Hill, North Carolina and currently employs 8 full-time employees. Tenax Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying and developing therapeutics that address cardio-pulmonary diseases with high unmet medical need. The firm's products include TNX-103 (oral levosimendan) and TNX-201 (oral enteric coated imatinib). The firm's lead product, Levosimendan, is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. TNX-201 is for the treatment of pulmonary arterial hypertension (PAH), which is a fatal orphan disease. The firm has completed Phase II clinical trial of levosimendan in North America for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF).

Company Info

TENAX THERAPEUTICS INC

101 Glen Lennox Drive, Suite 300

Chapel Hill NORTH CAROLINA 27560

P: 19198552100.0

CEO: Anthony DiTonno

Employees: 8

Website: http://www.tenaxthera.com/

TENX News

a day ago - ChartmillTop movers in Friday's session

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.

a day ago - ChartmillThese stocks are moving in today's session

Let's have a look at the top gainers and losers in the middle of the day of today's session.

2 days ago - ChartmillThese stocks are gapping in today's session

Let's have a look at what is happening on the US markets on Friday. Below you can find the gap up and gap down stocks in today's session.

2 days ago - ChartmillWhat's going on in today's pre-market session

Let's have a look at what is happening on the US markets before the opening bell on Friday. Below you can find the top gainers and losers in today's pre-market session.

2 days ago - Seeking AlphaTenax Therapeutics stock dips after pricing $15.6M securities offering (NASDAQ:TENX)

Tenax Therapeutics (TENX) shares fell 14% after the pharmaceutical company priced its $15.6M securities offering.The offering comrpises 8.66M shares of common stock (or pre-funded...

2 days ago - Tenax TherapeuticsTenax Therapeutics Announces Pricing of Approximately $15.6 Million Public Offering

CHAPEL HILL, N.C., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying,...

TENAX THERAPEUTICS INC (TENX) 1.75 -0.46 (-20.81%)

1.75 -0.46 (-20.81%)